Matthew Carroll, MD
Rheumatology · Keesler Afb, MSNPI 1124247341
Payments from drug & device makers
Across 1,115 payments — averaging $50.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$21K
- Amgen$9K
- Gilead$6K
- AbbVie$5K
- UCB, Inc.$2K
- Pfizer$2K
- plus $11K from 34 others
What the payments were for
- Consulting fees$7,87514%
- Speaking & faculty fees$20,36436%
- Travel & lodging$5,0039%
- Food & beverage$22,60640%
- Education$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 34 | $20,819 |
| Amgen(2 entities) | 218 | $8,909 |
| Gilead | 12 | $6,449 |
| AbbVie | 206 | $4,728 |
| UCB, Inc. | 118 | $2,311 |
| Pfizer | 112 | $1,807 |
| Boehringer Ingelheim | 18 | $1,649 |
| Novartis | 66 | $1,428 |
| E.r. Squibb & Sons, L.L.C. | 55 | $1,013 |
| GSK | 42 | $915 |
| Johnson & Johnson | 48 | $884 |
| Lilly USA, LLC | 38 | $861 |
| AstraZeneca(2 entities) | 36 | $780 |
| Sobi, Inc | 13 | $359 |
| Mallinckrodt Hospital Products Inc. | 12 | $346 |
| ANI Pharmaceuticals, Inc. | 14 | $324 |
| Insmed, Inc. | 2 | $323 |
| Lantheus Medical Imaging, Inc. | 1 | $320 |
| Vertex | 1 | $255 |
| Aurinia Pharma U.S., Inc. | 10 | $253 |
| Bristol Myers Squibb | 8 | $178 |
| Genentech USA, Inc. | 8 | $148 |
| Vifor (international) Ltd. | 1 | $140 |
| Sanofi | 5 | $125 |
| Sandoz | 6 | $121 |
| Radius Health, Inc. | 5 | $105 |
| Cardinal Health 110 LLC | 1 | $100 |
| Fresenius Kabi USA, LLC | 4 | $80 |
| Regeneron Healthcare Solutions, Inc. | 4 | $78 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Organon | 3 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Medexus Pharma, Inc. | 2 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Invivyd Inc | 1 | $15 |
| EMD Serono, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$56,078 in reported general payments places this provider in the 85th percentile of 44 rheumatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 176 | $1,612,530 |
| RinvoqUpadacitinib | 132 | $790,613 |
| KrystexxaPegloticase | 13 | $605,383 |
| Enbrel SureclickEtanercept | 49 | $409,759 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 33 | $252,427 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $230,810 |
| Actemra ActpenTocilizumab | 52 | $223,139 |
| KevzaraSarilumab | 53 | $222,194 |
| XeljanzTofacitinib Citrate | 37 | $189,909 |
| Orencia ClickjectAbatacept | 32 | $183,015 |
| Xeljanz XrTofacitinib Citrate | 34 | $181,284 |
| TremfyaGuselkumab | 12 | $167,315 |
| ForteoTeriparatide | 23 | $84,477 |
| OrenciaAbatacept | 11 | $43,087 |
| ActemraTocilizumab | 23 | $28,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $4,728 | $790,613132 claims |
| AmgenKrystexxa | $8,909 | $605,38313 claims |
| SanofiKevzara | $125 | $222,19453 claims |
| PfizerXeljanz | $1,807 | $189,90937 claims |
| Johnson & JohnsonTremfya | $884 | $167,31512 claims |
| Lilly USA, LLCForteo | $861 | $84,47723 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $1,013 | $43,08711 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $80 | $2415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 44 rheumatology providers in Mississippi.
Other rheumatology in Keesler Afb
- Alan BartholomewKeesler Afb$557
- Evan ManningKeesler Afb$243
- Vikas MajithiaJackson$1.4M
- David WeissHattiesburg$597K
- Kirk EddlemanOxford$576K
- Charles KingTupelo$404K
- Jason TaylorMadison$173K
- Neal ShparagoJackson$39K
- Seth ComptonMadison$22K
- Sharon HongFlowood$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.